A Multicenter Phase IB Dose Escalation Study to Evaluate the Safety, Feasibility and Efficacy of the Torisel-Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (T-R-CHOP), Torisel-Rituximab-Fludarabine-Cyclophosphamide (T-R-FC) and Torisel-Rituximab-Aracytine High Dose-Dexamethasone (T-R-DHA) for the Treatment of Patients in Relapsed/Refractory Mantle Cell Lymphoma.

Trial Profile

A Multicenter Phase IB Dose Escalation Study to Evaluate the Safety, Feasibility and Efficacy of the Torisel-Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (T-R-CHOP), Torisel-Rituximab-Fludarabine-Cyclophosphamide (T-R-FC) and Torisel-Rituximab-Aracytine High Dose-Dexamethasone (T-R-DHA) for the Treatment of Patients in Relapsed/Refractory Mantle Cell Lymphoma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs Temsirolimus (Primary) ; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Fludarabine; Prednisone; Rituximab; Vincristine
  • Indications Mantle-cell lymphoma
  • Focus Adverse reactions
  • Acronyms T3
  • Most Recent Events

    • 08 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 16 Oct 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
    • 22 May 2015 Planned End Date changed from 1 Jan 2015 to 1 sep 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top